PT UBC Medical Indonesia Tbk
PT UBC Medical Indonesia Tbk distributes medical devices in Indonesia. It operates in two segments, Medical Disposables and Consumables, and Diagnostics and Equipment. The company offers next generation molecular, retina AI, infectious disease, HPV DNA test, real time PCR, TB management, and newborn screening products. PT UBC Medical Indonesia Tbk was founded in 2014 and is based in Jakarta Timur… Read more
PT UBC Medical Indonesia Tbk (LABS) - Net Assets
Latest net assets as of September 2025: Rp150.72 Billion IDR
Based on the latest financial reports, PT UBC Medical Indonesia Tbk (LABS) has net assets worth Rp150.72 Billion IDR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp217.49 Billion) and total liabilities (Rp66.77 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp150.72 Billion |
| % of Total Assets | 69.3% |
| Annual Growth Rate | 146.73% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 167.99 |
PT UBC Medical Indonesia Tbk - Net Assets Trend (2021–2024)
This chart illustrates how PT UBC Medical Indonesia Tbk's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PT UBC Medical Indonesia Tbk (2021–2024)
The table below shows the annual net assets of PT UBC Medical Indonesia Tbk from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp138.75 Billion | +181.11% |
| 2023-12-31 | Rp49.36 Billion | +3.98% |
| 2022-12-31 | Rp47.47 Billion | +414.20% |
| 2021-12-31 | Rp9.23 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to PT UBC Medical Indonesia Tbk's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 757660600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rp4.82 Billion | 3.47% |
| Common Stock | Rp79.00 Billion | 56.94% |
| Other Comprehensive Income | Rp775.77 Million | 0.56% |
| Other Components | Rp54.16 Billion | 39.03% |
| Total Equity | Rp138.75 Billion | 100.00% |
PT UBC Medical Indonesia Tbk Competitors by Market Cap
The table below lists competitors of PT UBC Medical Indonesia Tbk ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PT Jobubu Jarum Minahasa Tbk
JK:BEER
|
$6.71 Million |
|
Magna Prima Bhd
KLSE:7617
|
$6.71 Million |
|
Celyad Oncology SA
PINK:CLYYF
|
$6.71 Million |
|
Total Metals Corp.
V:TT
|
$6.71 Million |
|
Hapbee Technologies Inc
PINK:HAPBF
|
$6.71 Million |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
$6.71 Million |
|
PT Hasnur Internasional
JK:HAIS
|
$6.71 Million |
|
Barksdale Resources Corp
OTCQX:BRKCF
|
$6.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PT UBC Medical Indonesia Tbk's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 49,360,018,000 to 138,754,543,000, a change of 89,394,525,000 (181.1%).
- Net income of 2,952,279,000 contributed positively to equity growth.
- Share repurchases of 71,400,000,000 reduced equity.
- Other comprehensive income increased equity by 321,841,000.
- Other factors increased equity by 157,520,405,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp2.95 Billion | +2.13% |
| Share Repurchases | Rp71.40 Billion | -51.46% |
| Other Comprehensive Income | Rp321.84 Million | +0.23% |
| Other Changes | Rp157.52 Billion | +113.52% |
| Total Change | Rp- | 181.11% |
Book Value vs Market Value Analysis
This analysis compares PT UBC Medical Indonesia Tbk's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 66.75x to 4.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | Rp2.34 | Rp156.00 | x |
| 2022-12-31 | Rp12.02 | Rp156.00 | x |
| 2023-12-31 | Rp12.50 | Rp156.00 | x |
| 2024-12-31 | Rp35.13 | Rp156.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PT UBC Medical Indonesia Tbk utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.00%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.47x
- Recent ROE (2.13%) is below the historical average (3.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 3.34% | 0.24% | 1.37x | 10.29x | Rp-614.95 Million |
| 2022 | 5.97% | 3.04% | 0.86x | 2.29x | Rp-1.91 Billion |
| 2023 | 4.44% | 1.60% | 0.85x | 3.25x | Rp-2.75 Billion |
| 2024 | 2.13% | 2.00% | 0.73x | 1.47x | Rp-10.92 Billion |
Industry Comparison
This section compares PT UBC Medical Indonesia Tbk's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $38,289,188,918
- Average return on equity (ROE) among peers: 3.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PT UBC Medical Indonesia Tbk (LABS) | Rp150.72 Billion | 3.34% | 0.44x | $6.71 Million |
| Nanotech Indonesia Global Tbk PT (NANO) | $38.29 Billion | 3.24% | 0.09x | $3.72 Million |